The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RMD | +3.8% | +21.17% | +3.91% | +43,778% |
| S&P | +12.26% | +86.71% | +13.3% | +1,147% |
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.34B | 9.1% |
| Gross Profit | $808.86M | 14.6% |
| Gross Margin | 60.56% | 2.9% |
| Market Cap | $40.08B | 11.7% |
| Market Cap / Employee | $3.78M | 0.0% |
| Employees | 10.6K | 6.2% |
| Net Income | $348.54M | 11.9% |
| EBITDA | $520.02M | 17.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.38B | 224.6% |
| Accounts Receivable | $958.42M | 12.1% |
| Inventory | 945.8 | 3.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $556.48M | -31.5% |
| Short Term Debt | $289.87M | 659.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 18.52% | 2.6% |
| Return On Invested Capital | 17.15% | 0.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $414.36M | 34.7% |
| Operating Free Cash Flow | $457.32M | 40.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 27.02 | 25.13 | 27.13 | 28.01 | -13.44% |
| Price to Book | 6.46 | 6.26 | 6.83 | 6.71 | -8.93% |
| Price to Sales | 6.85 | 6.56 | 7.37 | 7.65 | 2.05% |
| Price to Tangible Book Value | 18.34 | 16.36 | 16.71 | 16.31 | -30.12% |
| Price to Free Cash Flow TTM | 30.80 | 26.05 | 28.08 | 27.78 | -18.01% |
| Enterprise Value to EBITDA | 71.96 | 68.72 | 70.76 | 76.28 | -7.72% |
| Free Cash Flow Yield | 3.2% | 3.8% | 3.6% | 3.6% | 21.96% |
| Return on Equity | 25.7% | 25.8% | 25.9% | 25.4% | 7.84% |
| Total Debt | $839.74M | $839.77M | $851.81M | $846.35M | -0.46% |
We also talk about weight loss drugs and sleep apnea, and other stock market news.
The CPAP pioneer has a phenomenal track record of success, but should investors jump on board today?
RMD earnings call for the period ending June 30, 2022.
RMD earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
